February 7, 2014
The landscape of hepatitis C (HCV) management has undergone a near-fundamental transformation over the past couple of years. As new treatment options puff up like popcorn kernels on a hot stove and our understanding of the virus deepens, it's important to revisit what's changed -- and what further changes 2014 may hold in store.
Late in 2013, Andrea Cox, M.D., Ph.D., an associate professor of medicine at Johns Hopkins University School of Medicine, presented an update on HCV coinfection for an audience of HIV care providers. Read on for a summary of key points from her talk, including selected slides (which have been reposted with her permission).
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|What Does 2015 Hold in Store for HIV Research?|
|The Cynical Connectedness of Gilead's Hepatitis C Pricing and Anti-Diversion Policies|
|Why HIV Vaccines May Be Failing|
|New HIV Gene Therapy Shows Promise in Mice|
|Test for HIV, Hepatitis C and Hepatitis B Approved by FDA|
|Top 10 HIV Clinical Developments of 2014|